Every Form 4 that Ocular Therapeut (OCUL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OCUL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCUL filings page.
OCULAR THERAPEUTIX, INC (OCUL) reported that its Chief Operating Officer, Donald Notman, sold 1,099 shares of common stock on August 31, 2026, at a weighted average price of $10.24 per share in an open-market transaction. The sale was executed under a durable automatic sale instruction to satisfy tax withholding from restricted stock units vesting on August 29, 2026, and is described as non-discretionary. Following this transaction, Notman held 366,529 shares directly, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) officer Peter Kaiser, Chief Development Officer, reported a sale of 3,035 shares of common stock on August 24, 2026, at a weighted average price of $10.77 per share. The transaction was executed under a pre-arranged durable automatic sale instruction to cover tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. After this sale, Kaiser directly holds 264,378 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) insider Sanjay Nayak, Chief Strategy Officer, reported a sale of 1,897 shares of Common Stock on 2026-08-24 at a weighted average price of $10.78 per share. The shares were sold pursuant to a durable automatic Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding on RSUs vesting on 2026-08-22 and are described as non-discretionary. Following this transaction, Nayak directly holds 326,898 shares of OCUL common stock.
OCULAR THERAPEUTIX, INC (OCUL) reported that Chief Scientific Officer Jeffrey S. Heier sold 3,296 shares of common stock on August 24, 2026 at a weighted average price of $10.78 per share. The sale was made under a durable automatic sale instruction adopted on April 9, 2024 to effect a sell-to-cover election for tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. Following this transaction, Heier beneficially owns 318,326 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) reported insider activity by Executive Chairman, President and CEO Pravin Dugel. On August 24, 2026, he sold 21,649 shares of common stock at a weighted average price of $10.77 per share in open-market transactions, pursuant to a durable automatic Rule 10b5-1 sale instruction adopted on February 21, 2024, to satisfy tax withholding obligations related to restricted stock units vesting on August 22, 2026. Following this sale, he directly held 2,525,429 common shares. On August 25, 2026, his spouse transferred 50,092 shares as a bona fide gift to the Pravin Dugel 2024 Irrevocable Trust for no consideration; Dugel is trustee and lifetime sole beneficiary, and remains the beneficial owner. As a result, indirect holdings shifted from 50,092 shares held by spouse to 744,903 shares held through the trust.
OCULAR THERAPEUTIX, INC director and officer Pravin Dugel reported bona fide gifts of Common Stock. On June 16, 2026, he reported two gift transactions totaling 100,184 shares, including 50,092 shares transferred to his spouse for no consideration.
After these transactions, Dugel reports 2,547,078 shares held directly, 694,811 shares held indirectly through the Pravin Dugel 2024 Irrevocable Trust, and 50,092 shares held indirectly by his spouse.
Ocular Therapeutix director Charles M. Warden received new equity awards as part of board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, boosting his direct holdings to 100,464 shares.
He was also granted options for 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest in full on the first anniversary of the grant date, or earlier immediately before the next annual stockholder meeting, as long as he remains on the board.
Ocular Therapeutix director Adrienne L. Graves received new equity awards as part of her board compensation. She was granted 14,000 restricted stock units, each representing one share of common stock, increasing her direct common stock holdings to 64,000 shares after the award.
She was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest 100% on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving on the board.
Ocular Therapeutix Chief Financial Officer Jason Shand Robins received new equity awards as part of his compensation. He was granted 15,441 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 68,097 shares after the award. He was also granted an option to buy 14,024 shares of common stock at an exercise price of $8.74 per share, expiring in 2036. The RSUs vest over three years in three equal annual installments, and the stock option vests monthly over four years, both contingent on his continued service with the company.
Hong Seung Suh reported acquisition or exercise transactions in this Form 4 filing.
Ocular Therapeutix director Seung Suh Hong received new equity awards as part of board compensation. He was granted 14,000 restricted stock units, each representing one future share of common stock, and 44,000 stock options to buy common shares at $8.74 per share.
The awards vest in full on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, as long as he continues serving on the board. After the grant, he directly holds 60,933 common shares and 44,000 options.
Ocular Therapeutix director Richard L. Lindstrom, MD received new equity awards as board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, and 44,000 stock options with an exercise price of $8.74 per share expiring on June 9, 2036.
Both the RSUs and options vest 100% on the first anniversary of the grant date or, if earlier, immediately before the next annual meeting of stockholders, provided he continues to serve on the board. Following the RSU grant, he directly owns 260,933 common shares.
Ocular Therapeutix director Merilee Raines received new equity awards. On June 10, 2026, she was granted 14,000 restricted stock units, each representing one share of common stock, under the company’s 2021 Stock Incentive Plan.
Subject to her continued board service, these RSUs vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, whichever comes first. She also received stock options for 44,000 shares at an exercise price of $8.74 per share, expiring on June 9, 2036, with similar vesting conditions. Following the grant, she directly holds 60,933 shares of common stock, in addition to the new option award.
Ocular Therapeutix director Leslie J. Williams received new equity awards. On June 10, 2026, Williams was granted 14,000 shares of common stock as restricted stock units under the company’s 2021 Stock Incentive Plan. These RSUs vest in full after one year of continued board service or just before the next annual stockholder meeting.
Williams was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036, with the same one-year vesting schedule tied to continued board service. After these grants, Williams directly holds 65,433 shares of common stock and 44,000 stock options.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open-market sale of 14,828 shares of common stock at a weighted average price of $8.27 per share. The sale was made under a pre-established durable automatic sale instruction to cover tax withholding tied to restricted stock units vesting on June 1, 2026, and was not a discretionary trade. Following this transaction, she directly holds 300,079 shares of common stock.
Ocular Therapeutix director and officer Pravin Dugel reported automatic tax‑related sales and internal share transfers. On May 26, 2026, 21,156 shares of common stock were sold at a weighted average price of $8.20 per share under a durable automatic sale instruction to cover tax withholding from restricted stock unit vesting. Following this sale, Dugel held 2,597,170 shares directly. On May 28, 2026, 394,696 shares previously held by his spouse were transferred for no consideration to the Pravin Dugel 2024 Irrevocable Trust, where he is trustee and lifetime beneficiary, leaving 694,811 shares in the trust and 0 in the spouse account while maintaining his beneficial ownership.
Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,967 shares of common stock at a weighted average price of $8.20 per share on May 26, 2026, leaving him with 266,141 shares held directly.
According to the disclosure, these shares were sold under a durable automatic sale instruction adopted on April 9, 2024 to execute a sell-to-cover election for tax withholding related to restricted stock units vesting on May 22, 2026. The filing states that the sales do not represent a discretionary trade by Kaiser.
Ocular Therapeutix’s Chief Scientific Officer Jeffrey S. Heier reported an open-market sale of 3,018 shares of common stock at a weighted average price of $8.20 per share.
According to the footnotes, the sale was executed under a durable automatic sale instruction adopted on April 9, 2024 to effect a sell-to-cover election for tax withholding tied to restricted stock units vesting on May 22, 2026, and does not represent a discretionary trade. Following the transaction, Heier directly holds 320,350 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an open-market sale of 1,858 shares of common stock on May 26, 2026 at a weighted average price of $8.20 per share. The transaction was executed under a durable automatic sale instruction to effect a sell-to-cover election for tax withholding tied to restricted stock units vesting on May 22, 2026, and was not a discretionary trade. Following this sale, Nayak directly holds 328,795 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director Pravin Dugel reported a bona fide gift of 394,696 shares of Common Stock on April 9, 2026, transferred to his spouse for no consideration. The transfer was recorded as a gift disposition and reflects an internal family reallocation rather than a market sale.
After this transaction, Dugel continues to hold 2,618,326 shares directly. He also has indirect ownership of 394,696 shares held by his spouse and 300,115 shares held by the Pravin Dugel 2024 Irrevocable Trust, indicating a substantial remaining stake in the company.
Ocular Therapeutix director and officer Pravin Dugel reported an automatic sale of 20,056 shares of common stock at a weighted average price of $8.28 per share. According to the disclosure, the transaction was carried out under a durable automatic sale instruction adopted on February 21, 2024 to cover tax withholding obligations tied to restricted stock units vesting on February 22, 2026, and is described as not being a discretionary trade.
After this open-market sale, Dugel directly holds 3,013,022 common shares, and an additional 300,115 shares are reported as held indirectly through the Pravin Dugel 2024 Irrevocable Trust.
Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,810 shares of common stock at a weighted average price of $8.28 per share. The shares were sold under a durable automatic sale instruction to cover tax withholding from restricted stock units vesting on February 22, 2026. After this transaction, he directly owns 269,108 shares.
Ocular Therapeutix, Inc.’s Chief Scientific Officer Jeffrey S. Heier reported an automatic sale of 3,057 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share to cover tax withholding tied to restricted stock units that vested on February 22, 2026.
The transaction was executed under a durable automatic sale instruction adopted on April 9, 2024, meaning it was not a discretionary trade. After this sale, Heier directly held 323,368 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an automatic sale of 1,759 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share under a pre-arranged durable automatic sale instruction.
The sale was made to cover tax withholding obligations tied to the vesting of restricted stock units on February 22, 2026, and is described as non-discretionary. After this sell-to-cover transaction, Nayak directly held 330,653 shares of Ocular Therapeutix common stock.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open‑market sale of 3,510 shares of common stock at a weighted average price of $7.74 per share on February 20, 2026. The sale was executed under a durable automatic sale instruction adopted on June 1, 2024 to cover tax withholding from restricted stock units that vested on February 11, 2026, and is described as non‑discretionary. Following this transaction, Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director Richard L. Lindstrom, MD, bought shares of the company’s common stock in the open market. On this transaction date, he purchased 60,229 shares at a weighted average price of $7.66 per share, bringing his directly held stake to 246,933 shares.
Ocular Therapeutix Chief Operating Officer Donald Notman reported an automatic open-market sale of 11,446 shares of common stock at a weighted average price of $9.04 per share on February 12, 2026. The sale was executed under a durable automatic sale instruction to satisfy tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. Following this transaction, Notman directly owns 366,356 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak executed an automatic sale of 10,348 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The transaction was carried out under a durable automatic sale instruction to cover tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. After this sell-to-cover transaction, Nayak directly held 332,412 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director and officer Pravin Dugel reported an open‑market sale of 124,882 common shares at a weighted average price of $9.04 per share. The transaction was made under a durable automatic sale instruction adopted on February 21, 2024 to satisfy tax withholding obligations from restricted stock units vesting on February 11, 2026.
After this sale, Dugel holds 3,033,078 common shares directly.
Ocular Therapeutix Chief Medical Officer Nadia Waheed reported an open-market sale of 7,863 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The sale was made under a durable automatic sale instruction to cover tax withholding on vested restricted stock units and was not a discretionary trade. After this transaction, she directly holds 318,417 shares.
Ocular Therapeutix Chief Operating Officer Donald Notman reported two small sales of company common stock that were automatically executed to cover taxes on vested equity awards. On February 2, 2026, he sold 5,455 shares at a weighted average price of $9.14, tied to restricted stock units that vested January 30, 2026. On February 4, 2026, he sold 6,035 shares at a weighted average price of $8.54, related to restricted stock units that vested February 3, 2026. Both transactions were carried out under a durable automatic sales instruction letter dated May 13, 2022, and are described as non-discretionary sell-to-cover trades for tax withholding. After these transactions, Notman directly beneficially owned 377,802 shares of Ocular Therapeutix common stock.
Ocular Therapeutix’s Global Chief Commercial Officer, David Wayne Robinson, reported new equity awards. On January 21, 2026, he received 136,000 restricted stock units (RSUs) of common stock at a price of $0. Each RSU represents one share of common stock and will vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 416,000 shares of common stock at an exercise price of $11.42 per share. This option vests over four years: 25% of the underlying shares vest on the one-year anniversary of his first date of employment, and the balance vests in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 136,000 shares of common stock and 416,000 stock options.
Ocular Therapeutix interim CFO Jason Shand Robins reported receiving a stock option grant linked to common shares of the company. On January 20, 2026, he was awarded a stock option to buy 33,000 shares of Ocular Therapeutix common stock at an exercise price of $11.45 per share. The filing shows he beneficially owns 33,000 derivative securities directly after this grant. The option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on his continued service to the corporation.
Ocular Therapeutix Chief Legal Officer Todd Anderman reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units (RSUs), each representing one share of common stock, at a price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments thereafter, subject to continued service.
On the same date, he was also granted a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share and expiration on January 1, 2036. The option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date. After these transactions, he beneficially owned 152,468 shares of common stock directly.
Ocular Therapeutix Chief Commercial Officer Steve Lawrence Meyers reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and additional one-third portions vesting at the end of each of the next two years, subject to continued service.
He was also granted a stock option covering 197,650 shares of common stock at an exercise price of $11.82 per share. This option vests over four years in equal monthly installments of 1/48 of the shares beginning one month after the grant date, contingent on continued service. Following these transactions, he beneficially owned 217,628 shares of common stock directly.
Ocular Therapeutix reported new equity awards to its Chief Strategy Officer, Sanjay Nayak. On January 2, 2026, he received 64,900 restricted stock units, each representing one share of common stock, granted at $0 under the company’s 2021 Stock Incentive Plan.
Subject to his continued service, these RSUs vest over three years in three equal annual installments. He was also granted a stock option for 197,650 shares at an exercise price of $11.82 per share, vesting monthly over four years beginning one month after the grant date, also contingent on continued service. Following the RSU grant, he beneficially owned 342,760 shares of common stock directly.
Ocular Therapeutix, Inc. reported that its Chief Development Officer, Peter Kaiser, received new equity awards on January 2, 2026. He was granted 79,112 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to his continued service.
On the same date, he was also granted a stock option for 240,932 shares of common stock with an exercise price of $11.82 per share. This option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date, again contingent on continued service, and expires on January 1, 2036. Following these grants, he beneficially owned 271,918 shares of common stock, which includes 1,373 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
Ocular Therapeutix Chief Medical Officer Nadia Waheed reported new equity awards. On January 2, 2026, she received 79,112 restricted stock units (RSUs), each representing one share of common stock, at a grant price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in two equal annual installments, subject to her continued service.
On the same date, she was also granted a stock option for 240,932 shares of common stock at an exercise price of $11.82 per share. This option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on continued service. Following the RSU grant, she beneficially owned 326,280 shares of common stock directly, along with the newly granted option covering 240,932 shares.
Ocular Therapeutix, Inc. (OCUL) reported an insider transaction by its Chief Strategy Officer on a Form 4. On 11/24/2025, the officer sold 1,878 shares of common stock in a transaction coded “S,” at a weighted average price of $12.04 per share.
According to the footnotes, the sale was executed under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding obligations tied to the vesting of restricted stock units on November 22, 2025, and is described as non-discretionary. After this sale, the officer beneficially owned 277,860 shares of Ocular Therapeutix common stock in direct form.
Ocular Therapeutix (OCUL) Executive Chairman, President and CEO Pravin Dugel reported insider transactions on Form 4. On November 24, 2025, he sold 19,530 shares of common stock at a weighted average price of $12.04 per share under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding from restricted stock units vesting on November 22, 2025. These sales were not a discretionary trade.
After this sale, he directly owned 3,157,960 shares. On November 26, 2025, his spouse transferred 49,754 shares for no consideration to the Pravin Dugel 2024 Irrevocable Trust, and the same number of shares was recorded as acquired by the trust. Following this transfer, 300,115 shares were held indirectly through the trust, and the reporting person remained the beneficial owner of those securities.
Ocular Therapeutix, Inc. insider filing: Chief Development Officer Peter Kaiser reported selling 3,007 shares of Ocular Therapeutix common stock on 11/24/2025 at a weighted average price of $12.02 per share. The filing states these shares were sold under a durable automatic sale instruction adopted on April 9, 2024 to cover tax withholding obligations tied to restricted stock units that vested on November 22, 2025, and that the sales do not represent a discretionary trade by the reporting person.
After this transaction, Kaiser beneficially owns 191,433 shares of Ocular Therapeutix common stock, held directly. The filing notes that the 3,007 shares were sold in multiple trades at prices ranging from $11.74 to $12.28, and that detailed trade information is available on request.
Ocular Therapeutix, Inc. (OCUL) reported an insider transaction by its Chief Scientific Officer, Jeffrey S. Heier. On 11/24/2025, he sold 3,469 shares of common stock at a weighted average price of $12.04 per share, through multiple trades between $11.80 and $12.3207. The filing states this was an automatic sale under a durable instruction adopted on April 9, 2024, to cover tax withholding obligations related to restricted stock units that vested on November 22, 2025, and that the trades were not discretionary. Following this transaction, Heier beneficially owned 245,940 shares of Ocular Therapeutix common stock in direct ownership.
Ocular Therapeutix (OCUL) Form 4: Chief Business Officer Namrata Saroj reported a sale of 25,865 shares of common stock on 11/05/2025. The transaction was executed to satisfy tax withholding obligations tied to restricted stock units that vested on 11/04/2025, under a durable automatic sale instruction adopted on 02/04/2025. The weighted average sale price was $10.74, with trades ranging from $10.5875 to $10.8704. Following the sale, she beneficially owns 174,135 shares, held directly.
Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc. (OCUL), reported a non-discretionary sale of 11,132 shares of common stock on 10/08/2025 under a durable automatic sale instruction tied to a sell-to-cover election for the vesting of restricted stock units. The weighted-average price reported was $12.34, with individual sale prices ranging from $12.00 to $12.5114. Following the transaction, the reporting person beneficially owned 87,568 shares.
The sale was executed to satisfy tax withholding obligations and was not a discretionary trade by the reporting person. The reporting person adopted the automatic plan on 10/07/2024 and offered to provide detailed per-price sale information to the company or SEC staff upon request.
Officer sale under pre-set plan: An officer of Ocular Therapeutix, Inc. (OCUL) reported the sale of 9,653 shares of common stock under a durable automatic sale instruction intended to satisfy tax withholding on RSU vesting. The transactions were effected on 10/02/2025 as non‑discretionary sales tied to the reporting person’s sell‑to‑cover election for restricted stock units that vested on 10/01/2025.
The filing reports a weighted average sale price of $11.03 (trade prices ranged between $10.99 and $11.0697) and shows the reporting person retained beneficial ownership of 194,440 shares after the transactions. The form was signed by an attorney‑in‑fact and discloses the sale was pursuant to a plan adopted on 04/09/2024.
Insider sale to cover taxes on vested RSUs: The Chief Scientific Officer, Jeffrey S. Heier, reported sales of 10,502 shares of Ocular Therapeutix common stock on 10/02/2025 under a pre-existing automatic sale instruction. The disposals were non-discretionary sell-to-cover transactions tied to the vesting of restricted stock units on 10/01/2025.
Those shares were sold in multiple trades at prices ranging from $10.99 to $11.0866, with a reported weighted-average price of $11.04. After the sales, the reporting person beneficially owned 249,409 shares directly.